Association of familial history of diabetes or myocardial infarction and stroke with risk of cardiovascular diseases in four German cohorts by Mühlenbruch, Kristin et al.
1
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15373  | https://doi.org/10.1038/s41598-020-72361-4
www.nature.com/scientificreports
Association of familial history 
of diabetes or myocardial 
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christa Meisinger6,7, Annette Peters2,8,9,10, Alexander Kluttig11, Daniel Medenwald11,12, 
Manuela Bergmann13, Heiner Boeing13, Matthias B. Schulze1,2,14 & cornelia Weikert 3*
Since family history of diabetes is a very strong risk factor for type 2 diabetes, which is one of the 
most important risk factors for cardiovascular disease (CVD), it might be also useful to assess the 
risk for CVD. Therefore, we aimed to investigate the relationship between a familial (parents and 
siblings) history of diabetes and the risk of incident CVD. Data from four prospective German cohort 
studies were used: EPIC-Potsdam study (n = 26,054), CARLA study (n = 1,079), SHIP study (n = 3,974), 
and KORA study (n = 15,777). A multivariable-adjusted Cox regression was performed to estimate 
associations between familial histories of diabetes, myocardial infarction or stroke and the risk of 
CVD in each cohort; combined hazard ratios  (HRMeta) were derived by conducting a meta-analysis. The 
history of diabetes in first-degree relatives was not related to the development of CVD  (HRMeta 0.99; 
95% CI 0.88–1.10). Results were similar for the single outcomes myocardial infarction (MI)  (HRMeta 
1.07; 95% CI 0.92–1.23) and stroke  (HRMeta 1.00; 95% CI 0.86–1.16). In contrast, parental history of 
MI and stroke were associated with an increased CVD risk. Our study indicates that diabetes in the 
family might not be a relevant risk factor for the incidence of CVD. However, the study confirmed the 
relationship between a parental history of MI or stroke and the onset of CVD.
Family history of diabetes is a well-known and strong risk factor for the onset of  diabetes1,2 and was therefore 
included in many of the published diabetes prediction  models3,4 . Interestingly, this is dependent on the number 
of affected relatives and the degree of relationship. A previous study observed that the number of affected parents 
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and siblings might be more informative than general definitions of a family  history3. Besides a direct link to the 
risk of developing diabetes, a few studies indicate that a family history of diabetes might also play a role in the 
development of cardiovascular diseases (CVD), suggested by the strong relationship between the prevalence of 
diabetes and risk of cardiovascular  diseases5 as well as positive associations between family history of diabetes 
and cardiometabolic parameters. Accordingly, cross-sectional analyses observed that a family history of diabetes 
was associated with increased carotid artery intimal-medial  thickness6 or endothelial  dysfunction7. Moreover, 
parental history of diabetes was associated with higher levels of liver  enzymes8, indicating an increased CVD 
 risk9,10. In addition, the history of diabetes in male relatives was associated with a 1.4-fold (95% CI 1.1–1.7) higher 
risk for subclinical  atherosclerosis11. As these findings were derived from cross-sectional studies and restricted 
to intermediate cardiometabolic markers, it remains controversial whether a family history of diabetes has any 
effect on the risk of future CVD. To date, only a very few prospective cohort studies have investigated the impact 
of family history of diabetes on the risk of future cardiovascular endpoints, with conflicting  results12–15. Therefore, 
the present study hypothesized that diabetes in the family might be a relevant risk factor for the development of 
CVD in the future. Thus, the study aimed to investigate the associations between various patterns of a familial 
history of diabetes with the risk of incident CVD using data from four German cohort studies (EPIC-Potsdam 
study, CARLA study, SHIP study, KORA study). Accordingly, to confirm the general validity of the study find-
ings, the present study also investigated the well-known association between familial histories of stroke and MI 
with incident CVD.
Results
Table 1 shows the characteristics of the study participants from all four cohorts stratified by absence or presence 
of parental history of diabetes. Participants with a positive parental history of diabetes were more likely to be 
female and less educated. Moreover, participants with a positive parental history of diabetes were more likely 
to have prevalent hypertension, hyperlipidemia, or diabetes themselves and on average had a higher BMI and 
larger waist circumference. In addition, a positive family history of MI and stroke was also more likely in par-
ticipants with a parental history of diabetes. In EPIC-Potsdam and CARLA, participants with a positive family 
history were slightly younger than participants with a negative family history, in contrast to SHIP and KORA. 
As depicted in Table 2, the distribution of a familial history of diabetes, myocardial infarction and stroke was 
very similar across all four cohorts.
History of diabetes in the family and the risk of CVD. In all four cohort studies, the results from the 
Cox regression showed that a history of diabetes in any first-degree relative in the family was not significantly 
associated with a risk of developing CVD (Table 3). Consequently, the combined estimate from the meta-anal-
ysis was 0.99 (95% CI 0.88–1.10) for parental history of diabetes. As we adjusted for several anthropometric 
or lifestyle factors which might be included, and explain the relationship between diabetes in the family and 
incident CVD, unadjusted analyses (Supplemental Table S3) or adjustment for sex only (Supplemental Table S4) 
were also performed, which did not support relevant relationships between diabetes in the family and risk of 
CVD in the four cohorts. Of note, maternal history was associated with incident CVD in the crude and sex-
adjusted model, but it is mainly driven by the KORA study (Supplemental Tables S3 and S4). Results were similar 
for the single outcomes myocardial infarction (MI) and stroke (Table 3) with  HRMeta 1.07 (95% CI 0.92–1.23) for 
MI and  HRMeta 1.00 (95% CI 0.86–1.16) for stroke. Furthermore, additional adjustment for prevalent diabetes 
did not affect the estimates for parental history of diabetes with CVD, MI and stroke.
With regard to homogeneity between the four different cohort studies, we observed a low variance between 
the studies, parental history of diabetes with tau-squared ranging between 0.0 and 0.0039 and similar  HRsMeta. 
Although the CARLA study showed the largest difference from the respective cohorts, the low impact on the 
overall variance might be explained by the small sample size leading to a wider confidence interval.
History of stroke or MI in the family and the risk of CVD. In contrast to diabetes in any part of the 
family, MI or stroke in the family was related to an increased CVD risk in all cohorts but CARLA. The HRs (95%-
CI) for parental history of MI were 1.61 (1.32–1.95), 1.36 (1.01–1.83), 1.25 (1.08–1.46) and 1.23 (0.67–2.25) 
in EPIC-Potsdam, SHIP, KORA and CARLA, respectively.  HRMeta was 1.38 (95% CI 1.20–1.59) (Supplemental 
Table S1). A stronger association was observed for incident MI as a single outcome for all definitions of family 
history of MI; a parental history of MI showed an increased risk of  HRMeta 1.65 (95% CI 1.35–2.02). For incident 
stroke, the strongest associations were observed for a sibling history of MI with  HRMeta 1.52 (95% CI 1.02–2.26), 
and a family history of MI with  HRMeta 1.33 (95% CI 1.06–1.67) (Supplemental Table S1). Overall, strong asso-
ciations between parental history of stroke and incident CVD, stroke and MI were observed (Supplemental 
Table S2). For sibling history or family history of stroke, this association showed a stronger positive trend than 
for the parent-related CVD or stroke risk. In the case of MI, a stronger risk was observed for parental history of 
stroke, maternal history of stroke and family history of stroke, with  HRMeta 1.22 (95% CI 1.00–1.49), 1.31 (95% 
CI 1.10–1.57) and 1.33 (95% CI 1.00–1.76), respectively (Supplemental Table S2).
Mutual analyses of diabetes and CVD history. Cross-classifying family history of diabetes and CVD 
and mutual adjustment generally revealed a picture similar to the main analysis. We observed a positive associa-
tion for those with a positive CVD history with CVD risk, either alone  (HRMeta 1.41, 95% CI 1.05–1.89) or in 
combination with a family history of diabetes  (HRMeta 1.37, 95% CI 0.91–2.08). Similarly, in models with mutual 
adjustment of family history of diabetes and CVD, only family history of CVD was related to an increased CVD 
risk  (HRMeta 1.39, 95% CI 1.03–1.88).
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Discussion
The results of the present analyses based on four population-based German cohorts do not support that diabetes 
in the family is a relevant risk factor for the development of cardiovascular diseases (MI and/or stroke). Specifi-
cally, we found no association between parental history of diabetes and incident CVD consistently across the 
cohort studies and in the meta-analysis. However, the present study confirmed the relationship between CVD 
(MI and/or stroke) in the family and the onset of CVD.
While there is scientific evidence for the relationship between diabetes in the family and the risk of devel-
oping  diabetes1,2, we could not confirm the hypothesis that diabetes in the family might also be a relevant risk 
factor for the development of CVD. This is in contrast to previous studies which suggested a higher prevalence 
of CVD-related subclinical dysfunctions and risk factors such as increased carotid artery intimal-medial thick-
ness, endothelial dysfunction, adverse cardiometabolic biomarker profile or subclinical atherosclerosis in persons 
with diabetes in the  family6–8,11. However, these findings were derived from small intervention studies and were 
restricted to intermediate cardiometabolic markers; for a better comparison with our study findings, prospective 
cohort studies with incident CVD as the outcome need to be discussed. For example, in their study on developing 
combined risk prediction models for diabetes, CVD and chronic kidney disease (CKD), Alssema et al.14 reported 
a significant positive association between diabetes in the family and the combined outcome of diabetes, CVD and 
CKD. Additionally, they showed that diabetes in the family instead might play a stronger role in developing one 
Table 1.  Characteristics of the study populations in german cohort studies by status of parental history of 
diabetes. Presented values are means and standard deviation for continuous variables and relative frequencies 
for categorical variables if not otherwise stated. a Mean absolute frequencies across all imputations with varying 
numbers from one imputation dataset to the other. b Means and standard errors after application of multiple 
imputation (m = 5). c Education level obtained as < 10 years of school, = 10 years of school, > 10 years of school. 
d ≥ 12 years. e For 11,926 persons only; f parental history of MI and stroke, respectively.
EPIC-potsdamb CARLA SHIP KORA
Parental history 
D− (n ~ 19,464a)
Parental history 
D+ (n ~ 6,590a)
Parental history 
D− (n = 758)
Parental history 
D+ (n = 321)
Parental history 
D− (n = 3,038)
Parental history 
D+ (n = 936)
Parental history 
D− (n = 9,230)
Parental history 
D+ (n = 2,551)
Incident CVD 
cases (%) 2.9 2.4 4.8 1.6 9.7 9.3 8.6 9.0
MI cases (%) 1.4 1.3 2.5 0.6 6.1 6.3 5.4 6.0
Stroke cases (%) 1.5 1.2 2.2 0.9 4.5 3.7 4.9 5.3
Sex (% male) 39.8 34.3 56.7 47.7 49.3 43.9 49.2 45.7





38.0 38.8 88.3 93.1 38.9c 38.6c
Technical college 24.8 25.0 2.5 1.6 43.7c 48.3c
University degree 37.2 36.2 9.2 5.3 17.5c 13.1c 34.4d 30.0d
Smoking (%)
Never smoker 47.5 48.2 42.0 51.4 35.9 36.5 45.9 44.3
Former smoker 32.0 31.3 38.4 30.2 33.6 32.6 28.1 29.7
Current 
smoker < 20 cig./
day
14.9 14.6 11.6 11.2 21.7 19.7 10.2 11.3
Current 
smoker ≥ 20 cig./
day
5.52 5.9 8.1 7.2 8.8 11.2 15.9 14.8
Sports activity (%)
≥ 2 h per week 22.0 22.8 17.9 18.7 44.2 38.5 19.9 17.5
Anthropometry
BMI (kg/m2) 26.0 (4.19) 26.8 (4.69) 27.9 (0.16) 28.7 (0.28) 26.9 (4.73) 28.1 (4.83) 26.3 (4.3) 27.2 (4.5)
Waist circumfer-
ence (cm) 85.7 (12.8) 87.0 (13.4) 99.0 (0.44) 100.0 (0.75) 88.4 (14.0) 90.9 (13.3) 88.0 (13.0)
e 90.2 (13.1)e
Prevalent hyper-
tension (%) 47.0 49.2 76.1 76.0 49.4 56.7 33.4 39.0
Prevalent hyper-
lipidemia (%) 27.2 28.0 37.9 40.8 20.1 26.8 28.0 32.2
Prevalent diabetes 
(%) 3.6 8.7 10.2 19.0 6.2 12.1 2.2 5.8
Family history of 
MI (% positive) 16.6 25.4 22.4 27.1 13.5 23.4 17.5
f 29.6f
Family history of 
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or more of the respective diseases than MI or stroke in the family. This is in contrast to our findings, especially 
when comparing these results with our results for mutual adjustment of family history of diabetes and family 
history of CVD. With both types of family history information in the model, family history of CVD showed a 
strong increased and statistically significant risk for developing CVD, while a family history of diabetes did not. 
Table 2.  Distribution of a familial history of diabetes, myocardial infarction, and stroke in EPIC-Potsdam, 
CARLA, SHIP, and KORA.
EPIC-Potsdam (n ~ 26,054) CARLA (n = 1,079) SHIP (n = 3,974) KORA (n = 11,781)
% (n) % (n) % (n) % (n)
Diabetes
Parental history positive 25.3% (n ~ 6,590) 29.7% (n = 321) 23.6% (n = 936) 21.6% (n = 2,551)
Maternal history positive 17.5% (n ~ 4,562) 20.9% (n = 225) 16.3% (n = 646) 14.0% (n = 1,646)
Paternal history positive 10.3% (n ~ 2,687) 12.5% (n = 135) 9.0% (n = 359) 9.5% (n = 1,120)
Sibling history positive 5.7% (n ~ 1,473) 13.3% (n = 143) 7.0% (n = 272) –
Family history positive 28.4% (n ~ 7,410) 36.8% (n = 397) 27.7% (n = 1,099) –
Myocardial infarction
Parental history positive 16.7% (n ~ 4,361) 19.9% (n = 215) 13.1% (n = 519) 20.1% (n = 2,369)
Maternal history positive 5.5% (n ~ 1,425) 7.0% (n = 75) 4.0% (n = 157) 5.9% (n = 697)
Paternal history positive 12.3% (n ~ 3,202) 14.5% (n = 156) 9.7% (n = 386) 15.4% (n = 1,818)
Sibling history positive 3.0% (n ~ 775) 6.1% (n = 66) 3.6% (n = 140) –
Family history positive 18.8% (n ~ 4,903) 23.8% (n = 257) 15.8% (n = 629) –
Stroke
Parental history positive 19.4% (n ~ 5,055) 24.7% (n = 267) 16.3% (n = 647) 21.5% (n = 2,538)
Maternal history positive 11.5% (n ~ 2,986) 14.7% (n = 159) 8.6% (n = 341) 10.5% (n = 1,231)
Paternal history positive 9.1% (n ~ 2,374) 11.7% (n = 126) 8.3% (n = 331) 12.9% (n = 1,520)
Sibling history positive 2.4% (n ~ 624) 5.6% (n = 60) 3.0% (n = 116) –
Family history positive 21.2% (n ~ 5,519) 28.1% (n = 301) 18.1% (n = 719) –
Table 3.  Hazard ratios for varying histories of diabetes in the family for incident cardiovascular diseases 
(CVD), stroke and myocardial infarction (MI). a Adjusted for sex, education, prevalent hypertension, BMI, 
waist circumference, smoking status, sports activity, alcohol intake and prevalent hyperlipidemia. b Pooled 
hazard ratios were derived from random effects model (REM). Significant estimates with a 95% confidence 
interval greater than 1.0 are highlighted in bold.
Hazard  Ratioa (95% CI)
EPIC-potsdam 
(n ~ 26,054) CARLA (n = 1,079) SHIP (n = 3,974) KORA (n = 11,781) Pooled estimate b
Outcome: CVD
Parental history of 
diabetes 1.03 (0.83–1.29) 0.68 (0.37–1.24) 0.96 (0.75–1.24) 1.00 (0.86–1.17) 0.99 (0.88–1.10)
Maternal history 1.13 (0.91–1.40) 0.72 (0.37–1.42) 0.98 (0.75–1.28) 1.05 (0.89–1.24) 1.05 (0.93–1.18)
Paternal history 0.90 (0.64–1.27) 1.15 (0.52–2.53) 1.03 (0.68–1.55) 0.95 (0.75–1.21) 0.96 (0.81–1.14)
Sibling history 1.43 (0.94–2.17) 1.58 (0.90–2.78) 1.04 (0.73–1.47) – 1.25 (0.97–1.61)
Family history 1.14 (0.92–1.40) 1.12 (0.69–1.82) 0.92 (0.73–1.16) – 1.04 (0.90–1.21)
Outcome: MI
Parental history of 
diabetes 1.17 (0.87–1.59) 0.55 (0.23–1.30) 1.07 (0.79–1.44) 1.06 (0.88–1.29) 1.07 (0.92–1.23)
Maternal history 1.26 (0.93–1.72) 0.53 (0.19–1.49) 1.13 (0.81–1.56) 1.09 (0.88–1.34) 1.12 (0.96–1.30)
Paternal history 1.08 (0.71–1.66) 0.82 (0.25–2.67) 0.85 (0.50–1.45) 1.00 (0.74–1.35) 0.99 (0.79–1.23)
Sibling history 1.60 (1.01–2.54) 1.24 (0.56–2.76) 1.28 (0.84–1.94) – 1.39 (1.04–1.86)
Family history 1.34 (1.02–1.75) 0.83 (0.42–1.64) 1.03 (0.78–1.37) – 1.14 (0.90–1.44)
Outcome: Stroke
Parental history of 
diabetes 0.91 (0.68–1.22) 0.87 (0.38–2.03) 0.89 (0.60–1.32) 1.09 (0.90–1.33) 1.00 (0.86–1.16)
Maternal history 1.02 (0.76–1.37) 0.98 (0.40–2.39) 0.87 (0.57–1.33) 1.10 (0.88–1.37) 1.04 (0.88–1.22)
Paternal history 0.72 (0.41–1.26) 1.73 (0.58–5.11) 1.46 (0.79–2.69) 1.05 (0.77–1.44) 1.06 (0.79–1.43)
Sibling history 1.26 (0.48–3.28) 2.13 (0.95–4.74) 0.89 (0.54–1.49) – 1.25 (0.73–2.14)
Family history 0.97 (0.70–1.35) 1.62 (0.80–3.29) 0.86 (0.60–1.21) – 0.98 (0.76–1.27)
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Mutual adjustment indicated that a family history of CVD might contain information that is also included in a 
family history of diabetes, but not vice versa. This might explain the stronger association between MI or stroke in 
the family and CVD, as the outcome as family history of diabetes might contain less relevant information than a 
family history of MI or stroke. However, this cannot be compared with the results by Alssema et al.14, since they 
only reported on the final complete model. The difference between the study results and the relevance of risk 
factors might be explained by the extended outcome with diabetes and CKD compared to only CVD in our study. 
Relevant risk factors might be more stronger related to the other outcomes—diabetes and CKD—rather than 
CVD, which is not distinguishable with a combined outcome. The results were generally conflicting among the 
few studies in this  context12,13,15. On the one hand, it has been shown that diabetes in the family was a risk factor 
for coronary heart disease (OR 2.5, 95% CI 1.0–6.4) in women, but no such association was found in men (OR 
0.4; 95% CI 0.2–1.1)12. On the other hand, Park et al. reported an increased risk for atherosclerotic cardiovas-
cular diseases with a positive family history of diabetes (HR 1.10, 95% CI 1.05–1.15) in men, but no significant 
association among women (HR 0.98, 95% CI 0.92–1.05)13. However, these findings were based on sex-stratified 
analyses and are thus hard to compare with our results. Still, the importance of a family history of diabetes as a 
risk factor for cardiovascular disease remains controversial and information that is included in the construct of 
family history of diabetes is unknown. For incident diabetes, it was shown that with traditional anthropometric, 
lifestyle and genetic risk factors only 13% of the diabetes risk related to family history could be  explained2, and 
for incident CVD it might be even less. In our study, we adjusted for several anthropometric or lifestyle factors 
which might be included and explain the relationship between diabetes in the family and incident CVD. However, 
crude association analyses did not support relevant relationships between diabetes in the family and risk of CVD 
in the four cohorts. Of note, maternal history was associated with incident CVD, but it is mainly driven by the 
KORA study (Supplemental Table S3). It could also be suggested that prevalent diabetes might be the strongest 
risk factor for the development of CVD and already contains the information of a family history; however, when 
adjusting the association of parental history of diabetes for it in our study, the results did not change.
In contrast to diabetes in the family, the well-known association between CVD (MI or stroke) in the fam-
ily and the onset of CVD could be confirmed in the present study, which supports the general validity of our 
study findings. To date, numerous case–control studies have reported an approximately two- to fivefold higher 
prevalence of a positive family history among individuals with prevalent cardiometabolic diseases compared to 
 controls16–19. Large prospective cohort studies also observed a positive association between self-reported parental 
or family history and future risk of cardiometabolic diseases, with multivariable-adjusted relative risks ranging 
from 0.8 to 2.220–23. This is in line with our results.
While the present study included data from four German cohort studies, our investigation is the most compre-
hensive study on this topic. However, several limitations need to be considered. First, history of diabetes and CVD 
could obtain the chance of misclassification and uncontrolled confounding as the information on familial history 
based on self-reports. Furthermore, information on family history of diabetes and stroke in EPIC-Potsdam was 
obtained with the 5th follow-up and contained a lot of missing values. Therefore, for participants who had fatal 
CVD events before this follow-up, we did not have the information and might have constructed a more positive 
family history status by multiple imputation than it would be. However, by applying multiple imputation, we 
performed the most valid approach to handling missing data and confirmed our findings in three other German 
cohort studies. Still, studies showed differences in design, censoring, outcome definition and information on 
family history; however, standardized procedures were applied to achieve high quality data and all CVD cases 
were validated by medical records followed by an established protocol, and the observed associations did not 
show heterogeneity when combined with meta-analysis, which supports the general validity of our findings. 
Furthermore, we did not conduct sex-stratified analyses as reported in previous studies, however, this would affect 
the validity of our statistical models as the sample size would be small for the specific family history definitions 
and would rather be impossible for some cohorts.
In conclusion, our study does not support the hypothesis that diabetes in the family is a relevant risk factor 
for the development of cardiovascular diseases, including MI and stroke. However, the present study confirmed 
the relationship between a positive family history for CVD (MI or stroke) and the onset of CVD.
Methods
Study populations. Data from four different German cohort studies were used, the European Prospective 
Investigation into Cancer and Nutrition (EPIC)-Potsdam study, the Cardiovascular Disease, Living and Ageing 
in Halle (CARLA) study, the Study of Health in Pomerania (SHIP) and the Cooperative Health Research in the 
Region of Augsburg (KORA) study. All participants gave written informed consent. The studies followed the 
recommendations of the Declaration of Helsinki and were approved by the Ethics Committee of the Medical 
Association of the State of Brandenburg (EPIC-Potsdam), the Ethics Committee of the Medical Faculty of the 
University of Halle-Wittenberg (CARLA), University of Greifswald (SHIP), and by local authorities (KORA).
EPIC‑potsdam study. The EPIC-Potsdam study is a prospective cohort study conducted among the general 
adult population of Potsdam, Germany, and surrounding municipalities. Overall, 27,548 participants, mainly 
within an age range of 35 to 65 years, were recruited between 1994 and 1998. Baseline assessment included 
physical examinations, a personal interview and questionnaires regarding lifestyle and  nutrition24. Follow-up 
questionnaires were sent out every two to three years and were primarily used for determining the disease status 
of the  participants25.
To identify potential CVD cases, self-reports, death certificates or linkage with hospital information sys-
tems were used. To increase sensitivity, the questionnaire included additional questions about typical stroke 
 symptoms26. All identified potential CVD events were defined according to World Health Organization 
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Monitoring of Trends and Determinants in Cardiovascular Disease criteria and classified by the International 
Statistical Classification of Diseases, 10th Revision (ICD-10). The details about the case identification and clas-
sification were described  previously26. All verified incident cases of myocardial infarction (MI) and stroke up 
to September 2014 (5th follow-up round) were included. Information on diagnoses (diabetes, MI and stroke) 
occurring in the participants’ mother, father or siblings was obtained at the 5th follow-up round as well. After 
exclusion of participants with missing follow-up information (n = 589) or non-verified (n = 83) or prevalent 
(n = 822) cases of MI or stroke, 26,054 participants remained for the analysis. 359 MI cases and 363 stroke cases 
were observed within a mean follow-up time of 11 years. A multivariable multiple imputation was used to impute 
missing covariate information (age, sex, education, smoking status, physical activity, BMI, waist circumference, 
alcohol consumption, prevalent hypertension, prevalent hyperlipidemia) (n = 237) and missing family history 
information (n = 3,247). First, we included all variables of the analysis model in the imputation model and created 
a monotone pattern of missingness and second, we applied logistic regression with specifically defined models 
for all single family history variables in a next step.
CARLA study. The CARdiovascular Disease, Living and Ageing in Halle (CARLA) study is a prospective 
population-based cohort study of the elderly general population of the city of Halle in eastern  Germany27. The 
CARLA cohort comprises 1,779 participants, aged between 45–83 years at baseline (967 men, 812 women). The 
baseline examination took place between December 2002 and January 2006. The first four-year follow-up exami-
nation was performed from March 2007 to March 2010 (mean follow-up time: 4.01 years). The net sample (after 
exclusion of deceased or non-responding people) then comprised 1,436 subjects, consisting of 790 men and 646 
women aged between 50 and 87 years. In 2013, a second follow-up investigation was performed. The baseline 
and first follow-up examination consisted of a detailed medical examination (ECG, echocardiography, anthro-
pometric measures, blood pressure measurements, taking of blood samples) and a standardized, computer-
assisted interview. The second follow-up assessment comprised only a detailed computer-assisted interview and 
a blood pressure measurement. In addition, regular mortality follow-ups were carried out to get information on 
the vital status of the participants. In the case of a deceased person, the cause of death was defined as specified in 
the official death certificate compiled by the Federal Statistical Office.
The incidence of CVD was defined using self-reported Physician’s and physician (general practitioner) vali-
dated diagnoses of myocardial infarction or stroke between baseline and second follow-up. Type 2 diabetes was 
also defined using self-reported physician’s diagnoses of diabetes or intake of antidiabetic medication, coded 
according to the Anatomical Therapeutic Chemical Classification (ATC) system, where code A10 was selected 
to define the current use of antidiabetic medication. Information of a family history of diabetes, MI or stroke 
was obtained at the baseline examination.
After exclusion of participants with missing follow-up information (n = 227), non-verified CVD cases (n = 90), 
prevalent CVD at baseline (n = 94), missing covariate information (n = 24) or missing information regarding 
family histories of diabetes, MI or stroke (n = 265), 1,079 participants remained for the analysis. Within a mean 
follow-up time of 4.0 years, 21 MI cases and 20 stroke cases were observed.
SHIP study. The Study of Health in Pomerania (SHIP-0) is a cross-sectional population-based study conducted 
between 1997 and 2001 in West Pomerania,  Germany28. The total population comprised 213,157  inhabitants28. 
A sample from the population aged 20 to 81 years was drawn from population  registries28. A total of 7,008 per-
sons were sampled with 292 persons of each sex in each of the 12 5-year age  strata28. The net sample (without 
migrated or deceased persons) comprised 6,267 eligible  participants28. Selected persons received a maximum of 
three written  invitations28. In the case of non-response, letters were followed by a phone call or by home visits 
if contact by phone was not  possible28. In the end, the SHIP population comprised 4,308 participants (cor-
responding to a final response of 68.8%)28, and due to missing information in covariates (education, smoking 
status, physical activity, BMI, waist circumference, prevalent hypertension, total cholesterol) (n = 120) or family 
histories (n = 214), 3,974 participants remained for analysis.
Information on vital status was collected at regular intervals starting from the time of enrolment. Death cer-
tificates were requested from the local health authority at the place of death and coded by a certified nosologist 
according to the International Classification of Diseases, 10th revision (ICD10)28,29. Two internists independently 
validated the underlying cause of death and performed a joint reading together with a third internist in cases 
of  disagreement28,29.
Participants were censored at death or loss to follow-up. The number of months between baseline examina-
tion and censoring was used as the follow-up  length29. The median duration of follow-up was 11.3 years. During 
the 224,884 person-years of follow-up, 382 participants died due to cardiovascular disease or survived a stroke 
or a myocardial infarction.
KORA Augsburg study. The prospective population-based KORA Augsburg study was conducted in the region 
of Augsburg (Augsburg city, counties Aichach-Friedberg and Augsburg), in Southern Germany. Between 
1984/85 and 1999/2001, four independent cross-sectional surveys (S1–S4) were conducted among inhabitants of 
the study region aged between 25 and 74 years old (in the first survey, the participants were 25 to 64 years old)30.
Baseline information on sociodemographics, lifestyle, and medication intake was assessed, and a medical 
examination was performed. Family history for the respective diseases (diabetes, myocardial infarction and 
stroke) was defined as a parental history (yes vs. no).
All survey participants were followed up until 31 December 2009 to collect information on non-fatal stroke 
and MI cases via postal questionnaires. All self-reported incident cases of stroke and MI were validated through 
information from the treating physicians or the participants’ hospital records. In addition, regular mortality 
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follow-ups were carried out for all survey participants. In the case of death during the follow-up, death certificates 
were requested from the local health authorities and the main cause of death was determined.
Altogether, 17,604 KORA participants were available. After exclusion of 1,060 persons due to missing fol-
low-up information and 514 participants with prevalent MI or stroke, another 4,004 men and women has to 
be excluded due to missing values in the parental history and another 1819 persons due to missing covariate 
information (age, sex, education years, smoking status, physical activity, BMI, alcohol consumption, prevalent 
hypertension, prevalent hyperlipidemia). The data set for analysis included 11,781 study participants (5,708 men 
and 6,073 women). Within a mean follow-up time of 14.0 years, 652 MI cases and 592 stroke cases were observed.
Patterns of a familial history of diabetes, stroke and MI. We defined a positive family history of 
diabetes if either the participant’s father, mother or at least one sibling had  diabetes3. A positive parental history 
was defined as either the father or mother or both having  diabetes3. Paternal history was positive if the father 
was diagnosed with diabetes, maternal history if the mother was diagnosed with diabetes, and sibling history 
if one or more siblings had a diabetes  diagnosis3. The reference groups were always defined by the different 
definitions of familial history (family history, parental history, maternal history, sibling history), e.g. classifying 
individuals with maternal history; the reference group comprised those without a maternal history. The same 
definitions were applied for the different patterns of a familial history of stroke and MI. In KORA, information 
regarding a history of diabetes, stroke or MI in the family was only available for the father and mother, but not 
for the siblings.
Statistical analysis. As outcome variables, we defined incident MI, incident stroke and incident cardiovas-
cular disease (CVD) which contained either MI or stroke or both. For the analysis of a family history of diabetes, 
MI, or stroke with risk of MI, stroke or CVD, we applied Cox regression models adjusted for age, sex, education, 
body mass index (BMI), waist circumference, smoking behaviour, sports activity, alcohol consumption, preva-
lent hypertension and prevalent hyperlipidemia. Results from the Cox regression in the separate imputation 
datasets in EPIC-Potsdam were combined to an overall estimate by applying Rubin’s  rules31.
Additionally, we investigated the association of solely CVD, solely diabetes or both diabetes and CVD in the 
family with risk of CVD, MI or stroke. To further investigate whether family history of diabetes and CVD include 
the same information, we mutually adjusted family history of diabetes and family history of CVD for each other.
The associations derived from single cohort studies were pooled by applying the meta-analysis  (HRMeta); 
random-effects models were calculated according to DerSimonian and  Laird32. As a measure for heterogeneity, 
we calculated tau-squared, which indicates the between-study variance.
As a sensitivity analysis, we additionally adjusted the association analysis between parental history of diabetes 
and CVD, MI and stroke for prevalent diabetes. Statistical analyses were performed with SAS (Versions 9.3 and 
9.4, Enterprise Guide 6.1, SAS Institute Inc., Cary, NC, USA) or Stata 15.1 (Stata Corporation, College Station, 
TX, USA). For the computation of pooled estimates from the meta-analysis, we used PROC MIXED according 
to previously published  methods33,34.
Data availability
In accordance with German Federal and State data protection regulations, epidemiological data analyses of 
EPIC-Potsdam may be conducted upon application addressed to Prof. Dr. Heiner Boeing (boeing@dife.de). 
Each application has to pass a review process conducted by a scientific board. In KORA, for approved reasons, 
access restrictions apply to the data underlying the findings and thus they cannot be made freely available in 
the manuscript, the supplemental files, or a public repository. The data are subject to national data protection 
laws and restrictions were imposed by the ethics committee of the Bavarian Medical Association (“Bayerische 
Landesärztekammer”) to ensure data privacy of the study participants. However, access to the data can be applied 
for through an individual project agreement with KORA. Other interested authors can access the data in the 
same way the authors used to access the data. Applications for access to the data sets can be found at the follow-
ing link: https ://www.helmh oltzm uench en.de/en/kora-en/infor matio n-for-scien tists /parti cipat ing-in-kora/utili 
zatio n-ofkor a-data/index .html. With regard to the CARLA study, data access and blood sample use is possible 
in compliance with the rules and regulations of the CARLA steering committee. SHIP data are available upon 
request by means of a project agreement. Data can be applied for online (https ://commu nity-medic ine.de) and 
access to it is subject to approval by the Steering Committee of the Research Network for Community Medicine.
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